Skip to main content

Table 4 Most frequently (occurring in ≥5% of patients) reported adverse events

From: An open-label, sequential, dose-finding study of peginesatide for the maintenance treatment of anemia in chronic hemodialysis patients

Treatment-Emergent Adverse Event, no. (%)

Total n = 164

Upper respiratory tract infection

19 (11.6)

Diarrhea

16 (9.8)

Nausea

15 (9.1)

Vomiting

15 (9.1)

Cough

13 (7.9)

Dyspnea

13 (7.9)

Muscle spasms

13 (7.9)

Pyrexia

13 (7.9)

Headache

12 (7.3)

Asthenia

11 (6.7)

Fatigue

11 (6.7)

Back pain

10 (6.1)

Hypertension

10 (6.1)

Pain in extremity

10 (6.1)

Hypocalcemia

9 (5.5)

Hypotension

9 (5.5)